Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real‐world users
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Aim: To investigate real‐world glycaemic outcomes and goals achieved by users of the MiniMed 780G advanced hybrid closed loop (AHCL) system aged younger and older than 15 years with type 1 diabetes (T1D). Materials and Methods: Data uploaded by MiniMed 780G system users from 27 August 2020 to 22 July 2021 were aggregated and retrospectively analysed based on self‐reported age (≤15 years and >15 years) for three cohorts: (a) post‐AHCL initiation, (b) 6‐month longitudinal post‐AHCL initiation and (c) pre‐ versus post‐AHCL initiation. Analyses included mean percentage of time spent in AHCL and at sensor glucose ranges, insulin delivered and the proportion of users achieving recommended glucose management indicator (GMI < 7.0%) and time in target range (TIR 70‐180 mg/dl > 70%) goals. Results: Users aged 15 years or younger (N = 3211) achieved a GMI of 6.8% ± 0.3% and TIR of 73.9% ± 8.7%, while spending 92.7% of time in AHCL. Users aged older than 15 years (N = 8874) achieved a GMI of 6.8% ± 0.4% and TIR of 76.5% ± 9.4% with 92.3% of time in AHCL. Time spent at less than 70 mg/dl was within the recommended target of less than 4% (3.2% and 2.3%, respectively). Similar outcomes were observed for each group (N = 790 and N = 1642, respectively) in the first month following AHCL initiation, and were sustained over the 6‐month observation period. Conclusions: This real‐world analysis shows that more than 75% of users with T1D aged 15 years or younger using the MiniMed 780G system achieved international consensus‐recommended glycaemic control, mirroring the achievements of the population aged older than 15 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030 · cited 1×
“Investigations of these closed-loop therapies in various trials(24-26) and in different paediatric studies of automated insulin delivery systems have shown similar findings of improved glycaemic control, while decreasing or not increasing hypoglycaemia.(27-29)”
Background6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s006 · Cited by 847
Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring
Bergenstal, R. M., Beck, R. W., Close, K. L., Grunberger, G., Sacks, D. B., Kowalski, A., Brown, A. S., Heinemann, L., Aleppo, G., Ryan, D. B., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1581 · Cited by 684 · cited 1×
“While there is a clinically important difference between HbA1c and the GMI,(35) the latter provides a validated correlation between CGM metrics and managed glycaemia over time.(36) As GMI has become a CGM-derived standard for glycaemic control, it was used as a surrogate for HbA1c for determining treatment goal achiev…”
MethodGarg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585
Self-citationToward Defining the Threshold Between Low and High Glucose Variability in Diabetes
Monnier, L., Colette, C., Wojtusciszyn, A., Dejager, S., Renard, E., Molinari, N., & Owens, D. R. (2017) · Diabetes Care · doi:10.2337/dc16-1769 · Cited by 390
Bergenstal, R. M., Nimri, R., Beck, R. W., Criego, A., Laffel, L., Schatz, D., Battelino, T., Danne, T., Weinzimer, S. A., Sibayan, J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32514-9 · Cited by 344
Self-citationDiabetes distress among adolescents with type 1 diabetes: a systematic review
Hagger, V., Hendrieckx, C., Sturt, J., Skinner, T. C., & Speight, J. (2016) · Current Diabetes Reports · doi:10.1007/s11892-015-0694-2 · Cited by 338 · cited 1×
“Physiological and hormonal changes of puberty that affect insulin action and insulin requirements and multiple behavioural factors such as reduced engagement while transitioning to self-management, increased diabetes distress and fear of hypoglycaemia shared by both youth with T1D and their guardians/caretakers, are b…”
BackgroundBrown, S. A., Forlenza, G. P., Bode, B. W., Pinsker, J. E., Levy, C. J., Criego, A. B., Hansen, D. W., Hirsch, I. B., Carlson, A. L., Bergenstal, R. M., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0172 · Cited by 286
Collyns, O. J., Meier, R. A., Betts, Z. L., Chan, D. S. H., Frampton, C., Frewen, C. M., Hewapathirana, N. M., Jones, S. D., Roy, A., Grosman, B., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2250 · Cited by 276
Self-citationOne Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology
Breton, M. D., & Kovatchev, B. P. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0097 · Cited by 250 · cited 2×
“GMI and time spent in range were maintained for the 6-month observation period, which has previously been reported for other age groups using automated insulin delivery systems.(23,27,32) Partitioned insulin administration between system-initiated and user-initiated insulin delivery sheds some light on why younger Min…”
Background
Cited by
Choudhary, P., Kolassa, R., Keuthage, W., Kroeger, J., Thivolet, C., Evans, M., Ré, R., de Portu, S., Vorrink, L., Shin, J., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00212-1 · Cited by 204
Self-citationPetrovski, G., Campbell, J., Pasha, M., Day, E., Hussain, K., Khalifa, A., & van den Heuvel, T. (2023) · Diabetes Care · doi:10.2337/dc22-1692 · Cited by 108
Castañeda, J., Arrieta, A., van den Heuvel, T., Battelino, T., & Cohen, O. (2024) · Diabetes Care · doi:10.2337/dc23-1581 · Cited by 107
Self-citationForlenza, G. P., DeSalvo, D. J., Aleppo, G., Wilmot, E. G., Berget, C., Huyett, L. M., Hadjiyianni, I., Méndez, J. J., Conroy, L. R., Ly, T. T., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0578 · Cited by 99
“…than the present study (mean value of 75.8%, up to 78.9% and 81.3% TIR for the * 10% of pediatric and adult users with the recommended settings) 15 ; however, these data include outcomes for select users who took additional actions to enable the upload of their device data rather than outcomes…”
InfluentialReal-world evidence of automated insulin delivery system use
Considine, E. G., & Sherr, J. L. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0442 · Cited by 59
“39,40,51,53,55,58 Five of the studies reported either being fully supported by industry 40,52,54,55 or having received industry support.”
InfluentialThe role of automated insulin delivery technology in diabetes
Boughton, C. K., & Hovorka, R. (2024) · Diabetologia · doi:10.1007/s00125-024-06165-w · Cited by 57
Benhamou, P., Adenis, A., Lebbad, H., Tourki, Y., Heredia, M., Gehr, B., Franc, S., & Charpentier, G. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15008 · Cited by 35
Metadata
- Authors
- Arrieta, A., Battelino, T., Scaramuzza, A. E., Da Silva, J., Castañeda, J., Cordero, T. L., Shin, J., & Cohen, O.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2022-05-12
- Volume
- 24
- Issue
- 7
- Pages
- 1370-1379
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W4223439323
- Cited by
- 154
- References
- 14
- FWCI
- 20.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.